Influence of Vitamin D Supplementation on Lipid Levels in Polycystic Ovary Syndrome Patients: a Meta-analysis of Randomized Controlled Trials

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2020 Aug 11

PMID 32776821

Citations 6

Authors

Bihui Jin

Lingbo Qian

Xiaohua Fu

Jing Zhu

Jing Shu

Affiliations

Soon will be listed here.

Abstract

Objective: Observational studies have shown that circulating vitamin D (VitD) deficiency is associated with atherogenic lipid patterns among polycystic ovary syndrome (PCOS) patients. However, interventional studies have shown inconsistent results. The aim of this meta-analysis was to investigate how VitD supplementation influences lipid indices in PCOS patients.

Methods: The authors searched four electronic databases through August 2019 to identify randomized controlled trials (RCTs) that assessed the effect of VitD intervention on serum lipids among PCOS patients. Mean differences were generated for statistical evaluation.

Results: We included eight studies and performed nine comparisons across 467 participants. VitD supplementation reduced serum triglyceride levels (-11.88 mg/dL; 95% confidence interval [CI]: -17.03 to -6.73), total cholesterol (-9.09 mg/dL; 95% CI: -14.90 to -3.29), low-density lipoprotein cholesterol (-5.22 mg/dL; 95% CI: -10.32 to -0.13), and very-low-density lipoprotein cholesterol (-2.43 mg/dL; 95% CI: -3.69 to -1.17) compared with no VitD supplementation. However, high-density lipoprotein cholesterol levels showed no differences with or without VitD supplementation (-0.39 mg/dL; 95% CI: -1.39 to 0.61).

Conclusions: VitD supplementation improved serum lipid levels among PCOS patients, but serum high-density lipoprotein cholesterol levels were not changed. VitD intervention might benefit PCOS patients who are at high risk of an atherogenic lipid profile.

Citing Articles

Vitamin D levels and lipid profiles in patients with polycystic ovary syndrome.

Moieni A, Haghollahi F, Dashtkoohi M, Abiri A, Salari E, Najafi M BMC Womens Health. 2024; 24(1):472.

PMID: 39192256 PMC: 11351497. DOI: 10.1186/s12905-024-03294-7.

The Effect of Vitamin D Supplementation on Lipid Profiles: an Umbrella Review of Meta-Analyses.

Radkhah N, Zarezadeh M, Jamilian P, Ostadrahimi A Adv Nutr. 2023; 14(6):1479-1498.

PMID: 37657652 PMC: 10721514. DOI: 10.1016/j.advnut.2023.08.012.

Mechanisms Suggesting a Relationship between Vitamin D and Erectile Dysfunction: An Overview.

Crafa A, Cannarella R, Barbagallo F, Leanza C, Palazzolo R, Flores H Biomolecules. 2023; 13(6).

PMID: 37371510 PMC: 10295993. DOI: 10.3390/biom13060930.

Vitamin D and cardiovascular disease risk. A literature overview.

Cortese F, Costantino M, Luzi G, Di Marino S, Giordano P, Monitillo F Mol Biol Rep. 2022; 49(9):8925-8942.

PMID: 35364717 DOI: 10.1007/s11033-022-07373-6.

Vitamin D and Lipid Profiles in Postmenopausal Women: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.

Liu W, Wu Z, Zhu D, Chen G, Yan G, Zhang S Front Mol Biosci. 2022; 8:799934.

PMID: 34977158 PMC: 8719197. DOI: 10.3389/fmolb.2021.799934.

References

Javed Z, Papageorgiou M, Deshmukh H, Kilpatrick E, Mann V, Corless L . A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome. Nutrients. 2019; 11(1). PMC: 6356309. DOI: 10.3390/nu11010188. View

Menichini D, Facchinetti F . Effects of vitamin D supplementation in women with polycystic ovary syndrome: a review. Gynecol Endocrinol. 2019; 36(1):1-5. DOI: 10.1080/09513590.2019.1625881. View

Jaimungal S, Wehmeier K, Mooradian A, Haas M . The emerging evidence for vitamin D-mediated regulation of apolipoprotein A-I synthesis. Nutr Res. 2011; 31(11):805-12. DOI: 10.1016/j.nutres.2011.09.005. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Pechlaner R, Tsimikas S, Yin X, Willeit P, Baig F, Santer P . Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III. J Am Coll Cardiol. 2017; 69(7):789-800. PMC: 5314136. DOI: 10.1016/j.jacc.2016.11.065. View

Dias S, Sutton A, Ades A, Welton N . Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2012; 33(5):607-17. PMC: 3704203. DOI: 10.1177/0272989X12458724. View

Azziz R, Carmina E, Chen Z, Dunaif A, Laven J, Legro R . Polycystic ovary syndrome. Nat Rev Dis Primers. 2016; 2:16057. DOI: 10.1038/nrdp.2016.57. View

de Groot P, Dekkers O, Romijn J, Dieben S, Helmerhorst F . PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update. 2011; 17(4):495-500. DOI: 10.1093/humupd/dmr001. View

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W . Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006; 91(11):4237-45. DOI: 10.1210/jc.2006-0178. View

10.

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

11.

Fang F, Ni K, Cai Y, Shang J, Zhang X, Xiong C . Effect of vitamin D supplementation on polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Clin Pract. 2017; 26:53-60. DOI: 10.1016/j.ctcp.2016.11.008. View

12.

Ramagopalan S, Heger A, Berlanga A, Maugeri N, Lincoln M, Burrell A . A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010; 20(10):1352-60. PMC: 2945184. DOI: 10.1101/gr.107920.110. View

13.

Sanders K, Nicholson G, Ebeling P . Is high dose vitamin D harmful?. Calcif Tissue Int. 2012; 92(2):191-206. DOI: 10.1007/s00223-012-9679-1. View

14.

Irani M, Seifer D, Grazi R, Julka N, Bhatt D, Kalgi B . Vitamin D Supplementation Decreases TGF-β1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial. J Clin Endocrinol Metab. 2015; 100(11):4307-14. DOI: 10.1210/jc.2015-2580. View

15.

Follmann D, Elliott P, Suh I, Cutler J . Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol. 1992; 45(7):769-73. DOI: 10.1016/0895-4356(92)90054-q. View

16.

Foroozanfard F, Talebi M, Samimi M, Mehrabi S, Badehnoosh B, Jamilian M . Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Horm Metab Res. 2017; 49(8):612-617. DOI: 10.1055/s-0043-112346. View

17.

Asemi Z, Foroozanfard F, Hashemi T, Bahmani F, Jamilian M, Esmaillzadeh A . Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome. Clin Nutr. 2014; 34(4):586-92. DOI: 10.1016/j.clnu.2014.09.015. View

18.

Wang L, Lv S, Li F, Yu X, Bai E, Yang X . Vitamin D Deficiency Is Associated With Metabolic Risk Factors in Women With Polycystic Ovary Syndrome: A Cross-Sectional Study in Shaanxi China. Front Endocrinol (Lausanne). 2020; 11:171. PMC: 7136495. DOI: 10.3389/fendo.2020.00171. View

19.

Trummer C, Schwetz V, Kollmann M, Wolfler M, Munzker J, Pieber T . Effects of vitamin D supplementation on metabolic and endocrine parameters in PCOS: a randomized-controlled trial. Eur J Nutr. 2018; 58(5):2019-2028. PMC: 6647224. DOI: 10.1007/s00394-018-1760-8. View

20.

Anagnostis P, Tarlatzis B, Kauffman R . Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metabolism. 2017; 86:33-43. DOI: 10.1016/j.metabol.2017.09.016. View